Table 1.
Identification of driver gene mutations required for serous carcinogenesis in mouse model or in vitro carcinogenesis model
| Genotype | Knockout mouse model (Ref. 32) | |||
|---|---|---|---|---|
| Number of mice | STIC | Ovarian metastasis | Peritoneal metastasis | |
| BRCA1−/−, TP53MT, PTEN−/− | 4 | 4/4 (100%) | 1/4 (25%) | 1/4 (25%) |
| BRCA1+ /−, TP53MT, PTEN−/− | 12 | 10/12 (83%) | 6/12 (50%) | 8/12 (67%) |
| BRCA2−/−, TP53MT, PTEN−/− | 12 | 9/12 (75%) | 9/12 (75%) | 8/12 (67%) |
| BRCA2+ /−, TP53MT, PTEN−/− | 3 | 3/3 (100%) | 3/3 (100%) | 2/3 (67%) |
| TP53−/−, PTEN−/− | 6 | 4/6 (67%) | 0/6 (0%) | 0/6 (0%) |
| BRCA2−/−, TP53−/− | 11 | 11/11 (100%) | NR | 3/11 (27%) |
| Trangene | Transgenic mouse model (Ref. 39) | |||
|---|---|---|---|---|
| Number of mice | p53 signature | STIC | Invasive adenocarcinoma | |
| TAg | 34 | 34/34 (100%) | 34/34 (100%) | 19/34 (56%) |
| Introduced genetic factors | In vitro carcinogenesis model (Ref. 40) | |||
|---|---|---|---|---|
| Number of mice | Conlony formaiton on soft agar | Tumor formation (subcutaneous) | Tumor formation (intraperitoneal) | |
| DN‐p53 | 4 | 0 | 0 | 0 |
| DN‐p53, KRAS MT | 4 | 0 | 0 | 0 |
| DN‐p53, c‐Myc | 4 | 0 | 0 | 0 |
| DN‐p53, CA‐AKT | 4 | + | 0 | 0 |
| DN‐p53, KRAS MT c‐Myc | 4 | + | 4 | 4 |
| DN‐p53, KRAS MT, CA‐AKT | 4 | + | 4 | 4 |
Abbreviations: CA‐AKT, constitutively activated AKT; DN‐p53, dominant negative form of p53; MT, mutation; STIC, serous tubal intraepithelial carcinoma; TAg, SV40 T antigen.